Drug Trial Radar · NCT05161195
Roll-over Study to Allow Continued Access to Ribociclib
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
134
Actual
Start
Jul 7, 2022
Primary completion
Jun 28, 2030
Study completion Aug 14, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the long-term safety of ribociclib (LEE011) in combination with other drugs and provide post-trial access (PTA) to participants who are currently receiving treatment with ribociclib in combination with other drugs and continuing to have clinical benefit in a Novartis-sponsored global study that has reached its primary objective(s).
Conditions
- Metastatic Breast Cancer
Interventions
RibociclibDrug
Participants continue ribociclib as was administered in their parent study
LetrozoleDrug
Participants continue ribociclib in combination with letrozole as was administered in their parent study
AnastrozoleDrug
Participants continue ribociclib in combination with anastrozole as was administered in their parent study
GoserelinDrug
Participants continue ribociclib in combination with goserelin as was administered in their parent study
TamoxifenDrug
Participants continue ribociclib in combination with tamoxifen as was administered in their parent study
FulvestrantDrug
All participants continue ribociclib in combination with fulvestrant as was administered in their parent study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with treatment-emergent adverse events (AES)Time frame: From day of first dose of study medication to 30 days after last dose of study medication, up to 8 years
Locations
73 sites in 22 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers
Chandler, Arizona
Highlands Oncology Group
Fayetteville, Arkansas
Beverly Hills Cancer Center
Beverly Hills, California
Poudre Valley Hospital
Fort Collins, Colorado
Mid Florida Hematology And Onc Ctr
Orange, Florida
Summit Cancer Care
Savannah, Georgia
John D Archbold Memorial Hospital
Thomasville, Georgia
Duly Health and Care
Plainfield, Illinois
Indian Univ Health Goshen Center forCancer
Goshen, Indiana
Northern Light Mercy Hospital
Portland, Maine
Englewood Health
Englewood, New Jersey
The Valley Hospital-Luckow Pavillion
Paramus, New Jersey
Eastchester Center for Cancer Care
The Bronx, New York
University Hospitals of Cleveland Seidman Cancer Center
Cleveland, Ohio
Oklahoma Cancer Specialists and Research Institute
Tulsa, Oklahoma
Millennium Research Clin Develop
Houston, Texas
Novartis Investigative Site
San Juan, Argentina
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Natal, Rio Grande do Norte, Brazil
Novartis Investigative Site
Ijuí, Rio Grande do Sul, Brazil
Novartis Investigative Site
Florianópolis, Santa Catarina, Brazil
Novartis Investigative Site
São José do Rio Preto, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Qingdao, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Chongqing, Chongqing Municipality, China
Novartis Investigative Site
Shijiazhuang, Hebei, China
Novartis Investigative Site
Harbin, Heilongjiang, China
Novartis Investigative Site
Changsha, Hunan, China
Novartis Investigative Site
Nanjing, Jiangsu, China
Novartis Investigative Site
Suzhou, Jiangsu, China
Novartis Investigative Site
Changchun, Jilin, China
Novartis Investigative Site
Kunming, Yunnan, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
San José, CR, Costa Rica
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.